Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Majedie Investments Net Assets Fall As It Hikes Payout, Redeems Debt

Wed, 05th Dec 2018 11:56

LONDON (Alliance News) - Majedie Investments PLC on Wednesday reported a decrease in net asset value over its financial year due to making higher dividend payouts and redeeming debentures, as its biggest fund underperformed its benchmark.

At September 30, the investment trust's NAV per share with debt at par value was 334.3 pence, down 2.1.% compared to 341.6p last year. With debt at fair value, Majedie's NAV per share decreased slightly in the same period to 326.2p at September 30 from 327.8p the year before.

Majedie's NAV total return at par value was 0.9% and at fair value was 2.7%. The trust did, however, note the redemption of its 2020 9.5% debentures in December 2017, which diluted the NAV at par value by 1.6% and by 0.6% at fair value.

The trust said it redeemed the debenture in order to reduce its gearing "as markets were at all time highs". Majedie's gearing reduced to 10% at September 30 from 17% a year before.

A gearing ratio is a measure of financial leverage, meaning the degree to which a firm's operations are funded by equity capital versus creditor financing. A higher gearing ratio indicates a higher degree of leverage.

The trust's net assets decreased 2.1% to GBP178.6 million from GBP182.5 million last year.

Majedie's net assets were hurt by its increased dividend payout and by a premium paid on redeeming the 2020 debentures.

Majedie upped its total dividend payment for the year by 13% to 11.00 from the 9.75p last year.

The FTSE All Share Index rose by 5.9% in the period and the MSCI World Index gained 12.9%. Majedie has no overall benchmark; instead its funds have their own separate benchmarks.

The biggest contributors to the trust's net assets were funds run by its manager Majedie Asset Management. Majedie Investments holds a 17% stake in Majedie Asset Management.

Majedie Investments noted the Majedie Asset Management UK Equity Segregated portfolio, which represents 29% of Majedie Investments total assets, underperformed it benchmark.

The fund returned 3.0% net of fees to Majedie Investments, which is a 2.9% underperformance against its benchmark - the FTSE All Share Index. The biggest detractors from the fund were overweight positions in general retail, gold mining and fixed line telecoms. Specifically, overweight positions in Barrick Gold Corp and Saga PLC hurt the fund's performance, as was not holding AstraZeneca PLC, Majedie said.

Chief Executive Officer William Barlow said: "Against a background of rising political concerns notably Brexit in the UK, but also in the US and Europe and rising economic concerns as quantitative easing turns to quantitative tightening, interest rate rises due to inflationary concerns, early signs of leading economic indicators rolling over and the Chinese economy slowing; the company's positioning has been defensive throughout the year. In retrospect this was too early but the recent market turbulence suggests the defensive positioning will be more appropriate in the current year."

Shares in Majedie Investments were down 1.7% Wednesday at 264.50 pence each.

More News
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.